Also found in: Medical, Wikipedia.


A semisynthetic ergot alkaloid, C20H25N3O2, that stimulates uterine contractions and is used in its maleate form to treat or prevent uterine bleeding after childbirth or abortion.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
References in periodicals archive ?
Caption: FIGURE 2: Comparison of perioperative methylergonovine doses.
Although other methods have been proposed, histamine, adrenalin, dopamine, dobutamine, atrial stimulation and exercise, the administration of intracoronary methylergonovine is the most sensitive and specific diagnostic method to be performed safely for the patient (Yasue 2008).
The acquisition of Symbiomix and the Solosec franchise expands Lupin's branded women's health specialty business, which is presently anchored by Methergine (methylergonovine) tablets.
Intracoronary methylergonovine provocation testing resulted in near-total spasm of the right coronary artery after administration of only 5 [micro]g methylergonovine into the right coronary artery [Figure 1]d.
Intramuscular methylergonovine maleate (Methergine) is sometimes used to treat uterine atony but should not be used in women with hypertension because of vasoconstrictive properties (King & Brucker, 2011).
Caliskan E et al in a randomised controlled trial compared oral misoprostol 400ug(followed by 2 doses of 100ug 4 hours apart) with intravenous infusion of oxytocin, combination of misoprostol and intravenous oxytocin infusion and combination of methylergonovine and intravenous oxytocin infusion.
Management includes measures to stabilize the patient, uterine tamponade with Foley's catheter or rolled gauze packing, and medical therapies like estrogens, progestins, methylergonovine, danazol, and 15-methyl-prostaglandin F2alpha.
During the period January 1999 to April 2007, 2596 patients who underwent diagnostic coronary angiography for suspected ischemic heart disease and those patients who showed no evidence of hemodynamically significant CAD were subjected to intracoronary methylergonovine testing.
Women with postpartum hemorrhage received additional doses of oxytocin and other uterotonic agents including methylergonovine, prostaglandin F2 alpha, and prostaglandin E1, per the obstetrician's discretion.
The analysis of the pretest/posttest results showed an interesting finding specific to two obstetrical questions on medication administration of Methergine[R] (methylergonovine maleate) and ephedrine sulfate.
TABLE 6 Short-Term Preventive Treatments for Menstrual Migraine Timing of Preventive Group Examples Administration (d) * Standard [beta]-blockers, calcium -2 to +3 channel blockers, tricyclic antidepressants, anticonvulsants Nonsteroidal Naproxen sodium, -7 to +6 anti-inflammatory mefenamic acid drugs Ergot alkaloids Methylergonovine -1 to +2 maleate Hormonal Transdermal estradiol -2 to +5 Estradiol gel -2 to +5 Tamoxifen -14 to +3 Triptans Frovatriptan -2 to +4 Naratriptan -2 to +3 * Relative to the first day of menstrual bleeding.
Methylergonovine is the second uterotonic agent to try if oxytocin fails.